Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice.

MLA

Gómez, E., et al. “Longitudinal Outcomes of Obeticholic Acid Therapy in Ursodiol-Nonresponsive Primary Biliary Cholangitis: Stratifying the Impact of Add-on Fibrates in Real-World Practice.” Alimentary Pharmacology & Therapeutics, vol. 59, no. 12, June 2024, pp. 1604–15. EBSCOhost, https://doi.org/10.1111/apt.18004.

APA

Gómez, E., Montero, J. L., Molina, E., García-Buey, L., Casado, M., Fuentes, J., Simón, M. A., Díaz-González, A., Jorquera, F., Morillas, R. M., Presa, J., Berenguer, M., Conde, M. I., Olveira, A., Macedo, G., Garrido, I., Hernández-Guerra, M., Olivas, I., Rodríguez-Tajes, S., … Fernández-Rodríguez, C. M. (2024). Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice. Alimentary Pharmacology & Therapeutics, 59(12), 1604–1615. https://doi.org/10.1111/apt.18004

Chicago

Gómez, E, J L Montero, E Molina, L García-Buey, M Casado, J Fuentes, M A Simón, et al. 2024. “Longitudinal Outcomes of Obeticholic Acid Therapy in Ursodiol-Nonresponsive Primary Biliary Cholangitis: Stratifying the Impact of Add-on Fibrates in Real-World Practice.” Alimentary Pharmacology & Therapeutics 59 (12): 1604–15. doi:10.1111/apt.18004.